Welcome to our dedicated page for Abbott Laboratories news (Ticker: ABT), a resource for investors and traders seeking the latest updates and insights on Abbott Laboratories stock.
Abbott Laboratories (NYSE: ABT) is a globally recognized American multinational company headquartered in Abbott Park, Illinois. Founded in 1888, Abbott has established itself as a leader in medical devices and health care. The company manufactures and markets a wide range of products, including cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment, testing kits, and branded generic drugs.
Abbott's product portfolio includes pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays along with point-of-care diagnostic equipment. Approximately 60% of Abbott’s sales are derived from markets outside the United States, underlining its global reach and influence.
Recently, Abbott introduced the PROTALITY™ brand, a high-protein nutrition shake aimed at supporting weight loss while preserving muscle mass. This innovation reflects Abbott's commitment to addressing global health challenges such as obesity and muscle health. The company also continues to make strides in medical technology with advancements like the TriClip™ system for tricuspid valve repair, and the FreeStyle Libre continuous glucose monitoring systems, which have set new standards in diabetes management.
Abbott is not only focused on innovative product development but also on strategic partnerships and sustainability. The extension of their partnership with the Real Madrid Foundation, aimed at reducing childhood malnutrition and promoting healthy habits, is a testament to their commitment to global health improvements.
Financially, Abbott has demonstrated robust performance, as evidenced by its consistent dividend payouts and its inclusion in the S&P 500 Dividend Aristocrats Index. The company reported strong Q1 2024 results with significant growth in their core business segments, further supported by successful product launches and clinical innovations.
Abbott’s mission to help people live more fully at all stages of life drives their development of life-changing technologies across diagnostics, medical devices, nutritionals, and branded generic medicines. With a workforce of over 114,000 employees serving people in over 160 countries, Abbott continues to set benchmarks in the healthcare industry.
Abbott (NYSE: ABT) announced the CE Mark approval for its TriClip™ Transcatheter Tricuspid Valve Repair System, addressing tricuspid regurgitation (TR) with a minimally invasive solution. This next-generation device is designed for tailored repairs, improving treatment for patients unfit for open-heart surgery. With data from the TRILUMINATE study showing symptomatic improvements, TriClip G4 enhances cardiologists' ability to treat TR. Additionally, it received Health Canada approval, expanding access to this innovative therapy worldwide.
Abbott (NYSE: ABT) announced that its XIENCE stent has received CE Mark approval in Europe for a shorter duration of dual anti-platelet therapy (DAPT) of just 28 days, aimed at patients with high bleeding risk (HBR). This marks the shortest DAPT indication globally. Recent studies showed that one-month or three-month DAPT followed by aspirin monotherapy is safe for HBR patients. The findings reinforce the XIENCE stent's safety profile, showing no increase in cardiac events while significantly reducing severe bleeding, and Abbott is pursuing U.S. approval for the same indication.
Abbott has received FDA Emergency Use Authorization for its BinaxNOW™ COVID-19 Ag Self Test for asymptomatic, over-the-counter use. This allows individuals to access the test without a prescription, targeting a broader audience including children as young as two. Abbott plans to distribute the test through major retailers, emphasizing its affordability for regular and event-specific testing. The test provides results in 15 minutes and has demonstrated high performance metrics, including 84.6% sensitivity and 98.5% specificity, benefiting from Abbott's extensive manufacturing capabilities.
Abbott will announce its first-quarter 2021 financial results on April 20, 2021, before the market opens. A live webcast of the earnings conference call will follow at 8:30 a.m. CT. The event will be accessible on Abbott's Investor Relations website. Abbott, a global healthcare leader, provides a range of healthcare solutions, employing around 109,000 colleagues in over 160 countries. For further details, visit their official website.
Abbott has established the Abbott Pandemic Defense Coalition, a global partnership aimed at early detection and rapid response to pandemic threats. This innovative coalition connects global testing centers to identify new viruses, assess risks, and develop diagnostics swiftly. The initiative emerged from lessons learned during the COVID-19 pandemic and builds on Abbott's three-decade experience in viral surveillance. The coalition includes collaborations with various international institutions for effective monitoring and response to emerging health threats.
Abbott (NYSE: ABT) has launched the NeuroSphere™ Virtual Clinic, a groundbreaking technology approved by the FDA, designed to enhance patient care for those with chronic pain and movement disorders. This remote care platform allows patients to communicate with their physicians via secure video chat, enabling clinicians to prescribe new treatment settings remotely. NeuroSphere aims to overcome accessibility barriers, especially for those living far from care providers. Medicare will cover remote programming services as a telehealth benefit, expanding access to vital treatments.
Abbott has received FDA Emergency Use Authorization (EUA) for its Alinity™ m Resp-4-Plex assay, enabling simultaneous detection of SARS-CoV-2, influenza A, influenza B, and RSV. This assay utilizes a single swab and offers fast, efficient diagnosis crucial for effective treatment. Additionally, the EUA for Abbott's SARS-CoV-2 test includes asymptomatic cases and allows the pooling of samples. The Alinity m system enhances laboratory efficiency, supporting healthcare workers in managing respiratory viral infections during the pandemic.
Abbott has discovered a significant population of HIV elite controllers in the Democratic Republic of Congo (DRC), where 2.7-4.3% of individuals test positive for HIV antibodies yet have low to non-detectable viral loads without antiretroviral treatment. This research, published in EBioMedicine, may aid in developing new HIV treatments and vaccines. The findings highlight an unusual physiological phenomenon in the DRC and continue Abbott's commitment to HIV research through its Global Viral Surveillance Program, which has been operational for over 25 years.
Abbott's board of directors declared a quarterly common dividend of 45 cents per share, marking the 389th consecutive quarterly dividend since 1924. This dividend is payable on May 17, 2021, to shareholders of record by April 15, 2021. Abbott has increased its dividend payout for 49 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index.
The global infant nutrition market is projected to grow at a CAGR of 7.7%, reaching $61.6 billion by 2026. This growth is driven by a rising population of working mothers seeking convenient nutrition options. Companies like Else Nutrition (TSXV:BABY), Kraft Heinz Co (NASDAQ:KHC), Abbott Laboratories (NYSE:ABT), Danone (OTCQX:DANOY), and Walmart (NYSE:WMT) are capitalizing on this trend. Notably, Else Nutrition has launched a plant-based formula and expanded its distribution in North America through major retailers.
FAQ
What is the current stock price of Abbott Laboratories (ABT)?
What is the market cap of Abbott Laboratories (ABT)?
What does Abbott Laboratories specialize in?
What are some of Abbott’s recent product launches?
How much of Abbott’s sales are generated outside the United States?
What is Abbott’s PROTALITY™ brand?
How does Abbott support global health initiatives?
What is Abbott’s financial performance like?
How many employees does Abbott have?
Which continuous glucose monitoring system is Abbott known for?
What is Abbott's mission?
In how many countries does Abbott operate?
